Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12606000185561
Ethics application status
Approved
Date submitted
7/05/2006
Date registered
17/05/2006
Date last updated
9/01/2017
Type of registration
Prospectively registered

Titles & IDs
Public title
A Very Early Rehabilitation Trial
Scientific title
A Prospective Phase 3, multicentre, randomised controlled trial of efficacy (death and disability at 3 months) and cost effectiveness of very early rehabilitation (early and more frequent rehabilitation sessions) versus standard care (the rehabilitation care a patient would normally receive) in patients with acute stroke.
Secondary ID [1] 251716 0
No Secondary ID
Universal Trial Number (UTN)
U1111-1145-4204
Trial acronym
AVERT
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Stroke 1158 0
Condition category
Condition code
Stroke 1242 1242 0 0
Ischaemic
Physical Medicine / Rehabilitation 1243 1243 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Patients are randomised to receive very early rehabilitation within 24 hours of the onset of stroke and for up to 14 days. The rehabilitation consists of protocol specified rehabilitation sessions of short duration, related to the patients normal activities of daily living. The rehabilitation is implemented by physiotherapists and nurses. Blinded assesssment of outcome is performed at 3 and 12 months.
Intervention code [1] 1024 0
Rehabilitation
Comparator / control treatment
Standard acute care (the standard rehabilitation care provided at the hospital)
Control group
Active

Outcomes
Primary outcome [1] 1677 0
Modified Rankin Score
Timepoint [1] 1677 0
At 3 months
Secondary outcome [1] 3008 0
Death rate and the rate and severity of important medical events
Timepoint [1] 3008 0
At 3 months
Secondary outcome [2] 3009 0
All adverse events during the intervention period.
Timepoint [2] 3009 0
Day 0 - Day 14
Secondary outcome [3] 3010 0
Health related quality of life measure - AQoL
Timepoint [3] 3010 0
3 and 12 months
Secondary outcome [4] 3011 0
Cost effectiveness and cost utility
Timepoint [4] 3011 0
At 3 and 12 months
Secondary outcome [5] 3012 0
mRS
Timepoint [5] 3012 0
At 12 months
Secondary outcome [6] 3014 0
Dose response - Mobilisation dose and outcome. Therapy dose provided by therapists and nurses, and outcome as measured by Modified Rankin Score.
Timepoint [6] 3014 0
3 months
Secondary outcome [7] 3016 0
Staff injury during the intervention period
Timepoint [7] 3016 0
Day 0 - Day 14
Secondary outcome [8] 9377 0
Cognitive function using Montreal Cognitive Assessment (MoCA)
Timepoint [8] 9377 0
At 3 months
Secondary outcome [9] 312761 0
Time (days) to achieve unassisted walking over 50 metres
Timepoint [9] 312761 0
3 months
Secondary outcome [10] 312762 0
Length of hospitalisation (acute+ rehabilitation)
Timepoint [10] 312762 0
3 months
Secondary outcome [11] 312763 0
Mood measured using Irritability, Depression and Anxiety scale
Timepoint [11] 312763 0
3 and 12 months
Secondary outcome [12] 312764 0
Barthel Index
Timepoint [12] 312764 0
3 and 12 months
Secondary outcome [13] 312765 0
Proportion of patients walking unassisted
Timepoint [13] 312765 0
3 and 12 months

Eligibility
Key inclusion criteria
First or recurrent stroke diagnosis, haemorrhage or infarct, admitted to a stroke unit within 24 hours of onset of stroke symptoms. Patients must at least react to verbal commands.
Minimum age
18 Years
Maximum age
Not stated
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Pre stroke mRS of 3,4 or 5 (previous significant disability)Deterioration in patients condition in the first hour resulting in admission to ICU, surgery or documented palliative treatment.Concurrent diagnosis of rapidly deteriorating disease.Unstable coronary or other medical condition which is judged by the investigator to pose a hazard to the patient by involvement in the trial.A confirmed or suspected lower limb fracture preventing implemetation of the protocoltPA patients can be included if the treating physician permits and mobilisation within 24 hours is permitted.Patients cannot be concurrently recruited to drug or other intervention trials. Vital signs not within protocol specified normal limits.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Allocation is concealed via a central web based randomisation system. Randomisation occurs once the patient provides consent. The AVERT physiotherapist and Nurse are aware of the allocation. The patient, other staff and specifically the assessor remain blinded to the allocation. All online information is secured by use of password site entry, and data encryption procedures.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permutated blocks of various lengths will be used to ensure allocation concealment. A secure remote web based computer generated randomisation will be used, statified according to stroke severity. (NIHSS 1-7 Mild), (NIHSS 8 - 16 Moderate), (NIHSS greater than 16 Severe).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis
The study is powered to detect an absolute risk reduction (ARR) of death or a poor outcome of 7.1% or greater, based on the following rationale: (i) consensus among investigators and international advisors that an ARR of this magnitude would represent a clinically meaningful effect size (although there are no formal cost-effectiveness data to support this view); and (ii) 3 month figures from an Australian hospital (40.9%) and a hospital that has practiced early mobilisation over many years (31.8%) showing less death and institutionalisation, therefore greater independent survival. Clinicians at this centre have estimated that mobilisation accounts for 78% of this 9.1% benefit. This gives a final absolute difference of 7.1%. A sample of 2104 patients (1052 per arm) will provide 80% power to detect a significant intervention effect (2 sided, p = 0.05) with adjustments for 5% dropping- in and a 10% dropping-out.
The primary efficacy hypothesis is tested using the binary logistic regression model with a treatment group as an independent variable and the 3 months mRS outcome (dichotomized into mRS 0-2 as favourable outcome and mRS 3-6 as poor outcome) as the dependent variable, including baseline NIHSS and age as treatment covariates for adjustment purposes. The treatment effect will be presented as odds ratio (OR) with the corresponding 95% CI. This analysis will allow comparison with published outcomes of other acute stroke trials.
Statisitical analysis plan for this trial will be published prior to the analysis of data.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/06/2006
Actual
18/07/2006
Date of last participant enrolment
Anticipated
Actual
16/10/2014
Date of last data collection
Anticipated
Actual
1/11/2016
Sample size
Target
2104
Accrual to date
Final
2104
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA,VIC
Recruitment outside Australia
Country [1] 309 0
United Kingdom
State/province [1] 309 0
Scotland
Country [2] 310 0
Singapore
State/province [2] 310 0
Singapore
Country [3] 311 0
United Kingdom
State/province [3] 311 0
Northern Ireland
Country [4] 312 0
United Kingdom
State/province [4] 312 0
Wales
Country [5] 313 0
Malaysia
State/province [5] 313 0
Kuala Lumur
Country [6] 314 0
United Kingdom
State/province [6] 314 0
England
Country [7] 6625 0
New Zealand
State/province [7] 6625 0
Auckland

Funding & Sponsors
Funding source category [1] 1358 0
Government body
Name [1] 1358 0
NHMRC grant
Country [1] 1358 0
Australia
Primary sponsor type
Other
Name
National Stroke Research Institute
Address
245 Burgundy Street, Heidelberg VICTORIA 3084
Country
Australia
Secondary sponsor category [1] 1199 0
University
Name [1] 1199 0
Greater Glasgow Health Board
Address [1] 1199 0
Dalian HOuse
350 St Vincent Street
Glasgow
G3 8YT
Country [1] 1199 0
United Kingdom

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 2715 0
Austin Health
Ethics committee address [1] 2715 0
Ethics committee country [1] 2715 0
Australia
Date submitted for ethics approval [1] 2715 0
Approval date [1] 2715 0
26/05/2006
Ethics approval number [1] 2715 0
H2006/02515

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 35466 0
A/Prof Julie Bernhardt
Address 35466 0
Florey Institute of Neuroscience and Mental Health
245 Burgundy Street
Heidelberg, Victoria, 3084 Australia
Country 35466 0
Australia
Phone 35466 0
+61 3 9035 7072
Fax 35466 0
61 3 9035 2251
Email 35466 0
[email protected]
Contact person for public queries
Name 10213 0
Ms Fiona Ellery
Address 10213 0
245 Burgundy Street, Heidleberg, Victoria 3084
Country 10213 0
Australia
Phone 10213 0
+613 9035 7042
Fax 10213 0
+61 3 94962251
Email 10213 0
[email protected]
Contact person for scientific queries
Name 1141 0
Julie Bernhardt
Address 1141 0
245 Burgundy Street Heidelberg, VICTORIA 3084
Country 1141 0
Australia
Phone 1141 0
+613 9035 7072
Fax 1141 0
+61 3 94962251
Email 1141 0
[email protected]

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
Dimensions AIThe Montreal Cognitive Assessment2011https://doi.org/10.1161/strokeaha.111.619486
EmbaseAVERT2 (a very early rehabilitation trial, a very effective reproductive trigger): Retrospective observational analysis of the number of babies born to trial staff.2015https://dx.doi.org/10.1136/bmj.h6432
EmbaseEfficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): A randomised controlled trial.2015https://dx.doi.org/10.1016/S0140-6736%2815%2960690-0
EmbaseExploring threats to generalisability in a large international rehabilitation trial (AVERT).2015https://dx.doi.org/10.1136/bmjopen-2015-008378
EmbasePrespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT).2016https://dx.doi.org/10.1212/WNL.0000000000002459
EmbaseA very early rehabilitation trial after stroke (AVERT): a Phase III, multicentre, randomised controlled trial.2017https://dx.doi.org/10.3310/hta21540
EmbaseEarly mobilization after stroke is not associated with cognitive outcome findings from AVERT.2018https://dx.doi.org/10.1161/STROKEAHA.118.022217
EmbaseEconomic evaluation of a phase III international randomised controlled trial of very early mobilisation after stroke (AVERT).2019https://dx.doi.org/10.1136/bmjopen-2018-026230
EmbaseExploring post acute rehabilitation service use and outcomes for working age stroke survivors (<=65 years) in Australia, UK and South East Asia: Data from the international AVERT trial.2020https://dx.doi.org/10.1136/bmjopen-2019-035850
EmbaseUtility-weighted modified Rankin Scale: Still too crude to be a truly patient-centric primary outcome measure?.2020https://dx.doi.org/10.1177/1747493019830583
Dimensions AIFactors associated with time to independent walking recovery post-stroke2021https://doi.org/10.1136/jnnp-2020-325125
EmbaseFactors associated with paid employment 12 months after stroke in A Very Early Rehabilitation Trial (AVERT).2022https://dx.doi.org/10.1016/j.rehab.2021.101565
N.B. These documents automatically identified may not have been verified by the study sponsor.